cyrilzakka/clinical-trials huggingface dataset:
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in cancer clinical trials. Optional quality of life surveys will be used to learn more about how HIV and cancer and HIV and cancer treatment affect people.


Eligibility Criteria:
Inclusion Criteria:

* Participant can understand and is willing to sign a written informed consent document.
* HIV positive. Documentation of HIV-1 infection by means of any one of the following:

  * Documentation of an HIV diagnosis in the medical record by a licensed health care provider;
  * Documentation of receipt of antiretroviral therapy (ART) (i.e., at least two different medications that do not constitute a prescription for pre-exposure prophylaxis \[PrEP\]) by a licensed health care provider. Documentation may be a record of an ART prescription in the medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name;
  * HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL;
  * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.

Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).

WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay, or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), a Western blot, or a plasma HIV-1 RNA viral load.

* Patient was diagnosed with or treated for cancer within the last 5 years. Participants will qualify under one of three categories:

  * New, primary or recurrent diagnosis -Considering or currently receiving cancer treatment
  * Metastatic or locally advanced cancer - This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies.
  * Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy.
* Age ≥ 18 years.
* Participant presents to an AMC domestic clinical trial site for either clinical care or research.

Exclusion Criteria:

* Participants who do not fulfill the criteria as listed above are ineligible.
the Clinicaltrail of the Effection Which of Phrenic Block Using in Non-intubated Video-assisted Thoracoscopic Surgery

Putting 80 patients divided into group S（non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block） and group D（non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block）randomly,compare the volume of anesthetic and the number of increasing anesthetic during operation were compared between the two groups.If the date of group S greater than group D，it shows that the effect of anesthetic effect of group D is better than group S.

1. Put 80 patients divided into group S（non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block） and group D（non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block）randomly.
2. Compare the volume of anesthetic drugs between the two groups.
3. If the date of group S greater than group D，it shows that the effect of anesthetic effect of group D is better than group S.

Eligibility Criteria:
Inclusion Criteria:

* The patient agreed to perform non-intubated video-assisted thoracoscopic surgery, and informed the possibility of intraoperative tracheal intubation or thoracotomy.
* No conventional anesthesia contraindication, no history of thoracic surgery, good cardiopulmonary function.
* There is no severe adhesion and calcification in the thoracic cavity, and no artificial pneumothorax is affected.
* the patient has no serious anxiety or depression.
* Small surgical trauma, simple steps, short time.

Exclusion Criteria:

* Mallampati≥3.
* BMI≥26 kg/m2.
* Hemodynamic instability.
* INR≥1.5.
* Respiratory infection, persistent cough or airway mucus hypersecretion, high risk of reflux.
* nervous system disease,such as seizure or brain edema.
* Extensive pleural adhesions or once chest surgery.
* PaO2\<60mmHg or PaCO2\>50 mmHg.
* Central hypopnea syndrome.
* Lung isolation should be used to protect the healthy side of the lung.
* Complicated operation, large trauma, long time, lack of experience or poor cooperation in the surgical team.
* Contraindications to local anesthetic.
Contraceptive Counseling in the Postpartum Period

This is a prospective randomized control trial in which we propose an intervention in the immediate post-partum period to educate women about contraceptive options, particularly long acting reversible contraception (LARC) methods with an aim of increasing the amount of women who choose a LARC method.

Eligible participants will be identified in the post-partum period and will be randomized to one of two groups. The control group will receive the standard of care contraceptive counseling which includes any prenatal counseling they received as well as information from the nurse practitioner that rounds on them in the post-partum period. The intervention group will also receive the standard of care contraceptive counseling but will also watch a 10 minute video created by the CHOICE project which counsels on different contraceptive options. Both groups will fill out a pre-intervention questionnaire as well as a post-intervention questionnaire 24hrs later. The primary outcome will be which type of contraception each woman chooses. The secondary outcomes will include determining if the women come to their post-partum visits as well as if they get the method of contraception they chose on the post-partum floor.

Eligibility Criteria:
Inclusion Criteria:

* Women giving birth at University Hospitals Case Medical Center
* Patient of the Women's Health Center
* Women delivering only one child
* Women receiving contraceptive counseling from the nurse practitioner that cares for the postpartum unit

Exclusion Criteria:

* Severe neonatal complication at time of delivery (neonatal death, neonatal admission to the neonatal intensive care unit (NICU) except in cases of chorioamnionitis)
* Severe maternal complication at time of delivery (patient requiring intensive care unit care, patient requiring hysterectomy at time of delivery)
* Preterm delivery \<34 weeks
The Effective Concentration of Lidocaine With Fentanyl in Lumbar Epidural Anesthesia for Transurethral Resection of Prostate(TURP) in Elderly Patients

Epidural lidocaine is widely used in anesthesia for urologic or lower abdominal surgery because of its rapid onset. But the epidural anesthesia using high concentration of lidocaine may cause excessive motor block and unwanted side effects such as nausea, vomiting and hypotension.

This is a study to determine the effective concentration of lidocaine with fentanyl in lumbar epidural anesthesia for transurethral resection of prostate in elderly patients.


Eligibility Criteria:
Inclusion Criteria:

* ASA 1 -3, patients scheduled for TURP( transurethral resection of prostate) were included

Exclusion Criteria:

* Patients with any contraindication to epidural anesthesia were excluded.

  * cognitive impairment
  * coagulopathy
  * allergy to lidocaine
  * infection at the puncture site
Mobilization With Movement Versus Soft Tissue Mobilization in Patients With De Quervain Tenosynovitis

this study will investigate the effects of mobilization with movement in addition to soft tissue mobilization on pain and range of motion in patients suffering from De Quervain Tenosynovitis.

De quervain tenosynovitis also known as stenosing tenosynovitis is a condition which occur when tendons at the base of thumb pinched and become irritated. Several treatment options are available like ultrasound, Graston therapy, thrust or non-thrust manipulation, mobilization with movement, soft tissue mobilization but this study focus on 2 treatments to improve malalignment of the joint and also reduce pain. First treatment is mobilization with movement in which passive accessory mobilization from therapist while active mobility is performed by patient. Second technique is soft tissue mobilization in which passive glides are applied. The purpose of study is to make comparison between mobilization with movement and soft tissue mobilization.

Eligibility Criteria:
Inclusion Criteria:

* Male and female

  * 20 to 50 years
  * Subjects with pain in base of thumb (9)
  * Subject with positive fienklstein test

Exclusion Criteria:

* History of radiculopathy

  * History of systemic illness
  * History of connective tissue disorder
  * Rheumatoid arthritis
  * History of hand or wrist injury or acute trauma
  * Subject with negative fienklstein test
Granulocyte-monocyte Apheresis in Ulcerative Colitis

BACKGROUND: Granulocyte-monocyte apheresis has been proposed for the treatment of ulcerative colitis, although is limited by costs and variability of results.


Eligibility Criteria:
Inclusion Criteria:

* moderate UC with steroid-dependence and azathioprine intolerance or resistance
Medication Adherence Research in COPD Patients

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death, affects over 24 million people in the US and is the leading cause of disability with projected healthcare costs at almost $50 billion. The goal of this study is to identify novel and potentially powerful targets for behavioral interventions in COPD which has been understudied despite its tremendous detrimental impact on overall public health.

The Centers for Medicare and Medicaid Services (CMS) has specifically targeted COPD hospital readmissions as a meaningful quality outcome that could result in financial penalties highlighting the significant impact of COPD on our overall health system. The growing availability of efficacious medication, stands in stark contrast to the poor health outcomes experienced by COPD patients. One possible explanation for this gap is low rates of medication adherence; some studies report that only 25% of COPD patients take at least 80% of their prescribed medications. Pharmacy refill records indicate that adherence to COPD medications is significantly lower than adherence rates seen in other chronic illnesses including hypertension, diabetes, and congestive heart failure. Significant negative long term health outcomes may be magnified by non-adherence to prescribed medications in COPD.

This study proposes to systematically identify modifiable determinants of adherence in COPD based on the Theory of Self-Regulation in 360 patients with COPD. A novel and significant innovation of this study is the use of mobile health (mhealth) technology to objectively assess medication use. No previous study of self-regulation theory has utilized objective measure of adherence. A further innovation of the study is the use of ecological momentary assessment (EMA) of patient reported symptoms and beliefs to evaluate longitudinal associations between observation (patient symptoms) judgements (medication use to relieve symptoms), and reactions (self-efficacy, outcome expectancy, and medication beliefs) in real time. This study will be the first to objectively evaluate the application of the Self-Regulation Theory in COPD and to examine the long-term longitudinal impact of medication adherence on disease progression in a diverse sample.

Eligibility Criteria:
Inclusion Criteria:

* 40 years of age or older
* Physician diagnosis of COPD
* Prescribed a long-term controller medication for COPD
* Moderate COPD on the basis of meeting one of the following criteria:

  1. Gold Stage II-IV disease with forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ≤70% and FEV1 (% predicted) \<80% or
  2. One or more hospital admissions, two or more emergency department (ED) visits, or prescription of oral steroids for COPD exacerbation in the past 12 months or ever having used home oxygen
* Cognitive ability to provide informed consent

Exclusion Criteria:

- Non-English speaking
Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency

The purpose of this study is to evaluate the efficacy of hydrocortisone replacement therapy in patients with partial cortisol deficiency after traumatic brain injury or subarachnoid hemorrhage on cognitive function.

This is a controlled, randomized, double-blind, placebo-controlled, crossover, interventional study. The benefit of replacement in partial corticotropic failure on brain function (cognition), especially in cases with borderline low cortisol levels after stimulation is unknown.

Moreover, since glucocorticoids might affect hGH secretion, the effect of hydrocortisone on hGH secretion reflected by IGF-1 levels will be assessed. If IGF-1 is below 2 SD at the end of the study, hGH secretion will additionally be determined by a GHRH-arginine-test.

An improved cognition in TBI and SAH patients with partial corticotropic insufficiency would give a new treatment option in this population which may lead to better quality of life and an enhanced rehabilitation process.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (male and female) between 18 and 75 years
* 1 -12 month after TBI or SAH before prescreening
* Cortisol level 100-180 ng/ml after stimulation with ACTH
* Written informed consent by patient or a legally accepted representative

Exclusion Criteria:

* Pregnancy and lactation period (during study treatment)
* Concomitant or previous high-dose therapy with glucocorticoids; previous treatment with glucocorticoids will be accepted, if it has been low dose (i.e. lower than the Cushing threshold) and has been stopped at least 3 months before study participation
* Suspected or known hypersensitivity to hydrocortisone or any of its components
* Albumine less than 2,5 g/dl
* Suspected or known drug or alcohol abuse
* Planned treatment for thyroid dysfunction or a planned change in established thyroid treatment
* Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion.
* Participation in another clinical trial with investigational new drugs
* Severe medical or psychiatric disease
* Change of dosage of any other drug which might influence the corticotrope axis or cognitive function (e.g. antidepressive treatment) during the last 3 weeks
* Oral contraceptives
* Severe disturbances in articulation, visual faculty or hearing
* Any elective surgery or medical treatment planned in the observation period
* Intensive Care treatment
Public Health Emergency: SOLIDARITY TRIAL Philippines

This study is an adaptive, randomized, open-label, controlled clinical trial utilizing an adaptive design to compare effects of repurposed drugs with local standard of care alone on major inpatient hospital outcomes. This is performed worldwide in collaboration with WHO.


Eligibility Criteria:
Inclusion Criteria:

* Consenting adults (age ≥18) hospitalised with the following criteria will be included in the study:

  1. Probable or confirmed COVID-19 regardless of severity, i.e., mild, moderate and severe cases
  2. Not already receiving any of the study drugs
  3. Without known allergy or contraindications to any of the study drugs (in the view of the physician responsible for their care), and
  4. Without anticipated transfer within 72 hours to a non-study hospital.

Exclusion Criteria:

* Patients with contraindications to any of the study drugs.
Fecal Calprotectin: Cheap Marker for Diagnosing Acute Infectious Diarrhea

Every year more than 4 billion cases of diarrhea occur worldwide culminating in about 2.5 million deaths, almost all in the developing nations. Reliable diagnosis of patients with acute infectious diarrhea which could be appropriately managed with antibiotics at presentation still remains a formidable challenge to the clinicians. To address this issue of predicting microbiological infectious etiology for diagnosing acute infectious diarrhea, we would evaluate stools from all patients with acute diarrhea with culture, Guaiac based fecal occult blood test (FOBT), Calprotectin and lactoferrin assays simultaneously. This would be the first study evaluating fecal calprotectin as a diagnostic marker in acute diarrhea

There are about 4 billion cases of diarrhea worldwide i.e. about half the population of the world is affected with it once every year. Though the mortality because of it has reduced significantly still it contributes to more than 2.2 million deaths (4% of all deaths) and 5% of health loss due to disability annually. Most of these deaths are due to acute diarrhea, in the developing countries which rapidly causes dehydration unless adequately supplemented. Unlike many of the medical challenges, acute infectious diarrhea still remains a significant global health hazard. Adequate, appropriate treatment with proper antimicrobials not only shortens the morbidity, hospitalisation and costs to the society but also can be life saving in certain infectious diarrhea.

The biggest problem is the lack of accurate diagnostic modality to differentiate acute infections from non infectious diarrhea. Stool microscopy, Guaiac based fecal blood tests (hemoccult), lactoferrin assays and bacteriological culture have been used for this purpose till now. However none of these were of great help in the diagnostic algorithm of management of acute diarrhea. The gold standard to diagnose acute infectious diarrhea is of course the bacteriological culture. But its very expensive, time consuming and delays definite therapy. There is a need for something simple, cheap, fast and accurate to diagnose acute infectious diarrhea. In the present prospective study, we plan to evaluate the performance characteristics of fecal calprotectin in diverse group of patients referred to our hospitals. Its performance characteristics would be compared with that of lactoferrin and FOBT.

Eligibility Criteria:
Inclusion Criteria:

* All patients having acute diarrhea i.e. 3 or more stools per day or stool weight exceeding 200 grams lasting less than 15 days

Exclusion Criteria:

Patients having the following diagnosis as they might have high calprotectin levels not only because of the diarrhea per se but may also be because of the underlying pathology itself.

* Inflammatory bowel disease (Crohn's disease, ulcerative disease)
* Gastrointestinal malignancy (colorectal cancer, gastric cancer etc)
* Cirrhosis of liver
* Chronic pancreatitis
* Currently on non steroidal anti inflammatory therapy
* Younger than 1 year of age
The Effects of Music on Neck Pain

The effects of passive music listening on pain, anxiety and quality of life in patients with chronic neck pain in addition to physical therapy will be examined.

The aim of the study was to investigate the effects of passive music listening in addition to physical therapy on pain, anxiety and quality of life in patients with chronic neck pain.There is no study in the literature examining the relationship between music listening and physical therapy in chronic back pain. Since our study will be the first to investigate the subject, we foresee that it is scientifically important and will shed light on future studies. In addition, national or international publications are planned after the study is completed.

Eligibility Criteria:
Inclusion Criteria:

* patients with neck pain for more than 3 months with pain severity of 5 or greater according to the visual analogue scale (VAS)

Exclusion Criteria:

* individuals who regularly take painkillers or anti-depressant and cortisone; and individuals having severe chronic illness and spine surgery were excluded from the study
The Effects of Platelet Rich Plasma on the Integrity of Rotator Cuff Repair

The purpose of this study was to determine the effect of platelet-rich fibrin matrix (PRFM) augmentation to at-risk arthroscopic rotator cuff repairs on healing rates and functional outcome scores. The investigators performed an observational cohort study in which a consecutive series of patients with rotator cuff tears at risk for retear was prospectively evaluated after arthroscopic repair augmented with PRFM. Clinical and magnetic resonance imaging (MRI) outcomes of the PRFM-augmented repairs were compared with historical controls with similar at-risk tears without PRFM augmentation.

Increased age, larger tear size, and more advanced fatty degeneration of the rotator cuff musculature have been correlated with poorer healing rates after rotator cuff repair. Platelets are an endogenous source of growth factors present during rotator cuff healing.

The investigators hypothesis is that augmentation of rotator cuff repairs with platelet-rich fibrin matrix (PRFM) may improve the biology of rotator cuff healing and thus improve functional outcome scores and retear rates after repair.

Rotator cuff tears at risk for retear were prospectively identified using an algorithm; points were assigned for age (50-59 years = 1; 60-69 years = 2; .70 years = 3), anterior-to-posterior tear size (2-2.9 cm = 0; 3-3.9 cm = 1; .4 cm = 2), and fatty atrophy (Goutallier score 0-2 = 0; Goutallier score 3-4 = 1). Three points were required for enrollment. Arthroscopic rotator cuff repair was performed with the addition of PRFM. Preoperative and 1-year postoperative magnetic resonance imaging (MRI) and functional outcome scores were obtained. Imaging and functional outcomes were compared with historical controls meeting the same enrollment criteria.

Enrollment for the study began in September 2008 and continued until March 2010.

Eligibility Criteria:
Inclusion Criteria:

* Algorithm score greater and equal to 3
* Both men and women over the age of 50
* Full-thickness rotator cuff tear at least 2 cm in size
* Tear repairable by arthoscopic-only techniques

Exclusion Criteria:

* Inflamation joint disease
* Active use of oral steroids
* Irreparable rotator cuff tear
* Subscapularis tear requiring open repair
* Claustrophobia
* Prior rotator cuff sugery on the affected shoulder
* Failure to return for follow-up magnetic resonance imaging scan